Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Expenditures on Prurisol were approximately $4.1 million during the year ended June 30, 2018. We expect expenditures on Prurisol to continue in future reporting periods, as we complete analysis of the study. We have entered into multiple non-disclosure agreements with pharmaceutical companies that enable us to continue ongoing discussions regarding potential partnering should the trial results support such a relationship


So here are my questions: Is IPIX analyzing the data or does the CRO? When we received the data lock I thought it was all good with the CRO and then our team gets dirty and has to dissect the data? Does anyone know?

The above also makes it sound like IPIX can discuss the trial info as they find out more and more with BP, during this completing analysis period. I'd love a clarification from Leo on how this P phase 2b data analysis goes down. Why do we owe the money? etc...